Long term, high dose interferon-alpha treatment in HTLV-I-associated myelopathy/tropical spastic paraparesis: a combined clinical, virological and immunological study
Authors:
- 1 April 1997
- journal article
- clinical trial
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 147 (2) , 135-144
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
- Ministry of Health, Labour and Welfare
This publication has 38 references indexed in Scilit:
- Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN–α) during therapy for chronic hepatitis CClinical and Experimental Immunology, 1994
- Human T-cell leukaemia virus type I and neurological diseaseCurrent Opinion in Neurobiology, 1993
- Systemic interferon-alpha in the treatment of HTLV-I-associated myelopathyActa Neurologica Scandinavica, 1992
- Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological diseaseNature, 1990
- Suppressive effects of interferons on the production and release of human T-lymphotropic virus type-I (HTLV-I)Archives of Virology, 1990
- Treatment of Chronic Hepatitis C with Recombinant Interferon AlfaNew England Journal of Medicine, 1989
- ANTIBODIES TO HUMAN T-LYMPHOTROPIC VIRUS TYPE-I IN PATIENTS WITH TROPICAL SPASTIC PARAPARESISThe Lancet, 1985
- Recombinant Leukocyte Interferon Treatment of Chronic Hepatitis BHepatology, 1985
- Rating neurologic impairment in multiple sclerosisNeurology, 1983
- New diagnostic criteria for multiple sclerosis: Guidelines for research protocolsAnnals of Neurology, 1983